Overview

* Alpha Teknova ( TKNO ) Q3 revenue up 9% yr/yr, beating analyst expectations

* Company reaffirms 2025 revenue guidance of $39-42 mln

* Gross margin improved to 30.7% from 0.9% due to prior yr non-recurring charges

Outlook

* Alpha Teknova ( TKNO ) reaffirms 2025 revenue guidance of $39-42 mln

* Company anticipates 2025 Free Cash Outflow of less than $12 mln

* Teknova sees long-term growth from customer relationships and product diversity

Result Drivers

* LAB ESSENTIALS GROWTH - Revenue from Lab Essentials products increased, offsetting lagging Clinical Solutions sales

* CUSTOMER RELATIONSHIPS - Rising number of Clinical Solutions customers despite challenging funding environment

* OPERATIONAL PERFORMANCE - Improved operational performance contributed to revenue growth, per CFO Matt Lowell

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $10.45 $10.30

Revenue mln mln (5

Analysts

)

Q3 EPS -$0.08

Q3 Net -$4.29

Income mln

Q3 Gross $3.21

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Alpha Teknova Inc ( TKNO ) is $10.00, about 50.5% above its November 5 closing price of $4.95

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)